Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Sezary Syndrome 1Neuroblastoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 9fludarabine 8Interleukin-2 8aldesleukin 7Sunitinib 6Everolimus 6Bevacizumab 6fludarabine phosphate 5Sorafenib 5Radiotherapy 4Nivolumab 4Gene Expression Profiling 4Filgrastim 4pembrolizumab 3peginterferon alfa-2b 3Stem Cell Transplantation 3Radiotherapy, Intensity-Modulated 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3cabozantinib 2atezolizumab 2Thiotepa 2Sodium Chloride 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Mycophenolic Acid 2Mesna 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Kidney Neoplasms × Interleukin-12 × Clear all
NCT01457131 2019-01-08

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled
DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡